Vision Improvement after Osimertinib Treatment in Paraneoplastic Optic Neuropathy Associated with Lung Adenocarcinoma
Open Access
- 15 July 2021
- journal article
- case report
- Published by Hindawi Limited in Case Reports in Ophthalmological Medicine
- Vol. 2021, 1-7
Abstract
Treatments for paraneoplastic optic neuropathy (PON), a tumor-related autoimmune disease, include immunosuppression, plasma exchange, and immunoglobulin therapies, as well as treatment of the underlying disease. Herein, we describe the clinical course of an older adult patient with PON whose loss of vision improved after switching between epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatments for cancer. A 76-year-old woman, who had been treated with gefitinib for lung adenocarcinoma for two years, presented with acute bilateral visual disturbances. Her decimal best-corrected visual acuity (BCVA) was 0.3 in the right eye (RE) and 0.7 in the left eye (LE). Slit-lamp examination and funduscopy showed no abnormal findings. Two weeks later, her BCVA decreased to 0.2 in the RE and 0.01 in the LE. Goldmans perimetry showed a defect in the lower nasal RE and extensive visual-field loss in the LE. Single-flash electroretinograms showed normal amplitudes. Magnetic resonance imaging revealed left optic neuritis and showed neither metastatic cancer nor multiple sclerosis. Pattern-reversal visual evoked potentials showed decreased P100 amplitudes in both eyes (BE). Based on a diagnosis of PON from clinical findings, methylprednisolone pulse treatment was administered. However, her BCVA became no light perception in BE two months after the first visit. Because the tumor tissue was found to be positive for the EGFR T790M resistance mutation by bronchoscopy, the EGFR-TKI treatment was changed to osimertinib, decreasing the size of the lung cancer lesions. Her BCVA improved to hand motion in BE. Her final BCVA was 0.01 in the RE, counting fingers 10cm in the LE. She died at the age of 79 years. To our knowledge, no reports have shown improvement in BCVA in patients with PON after changing EGFR-TKI treatments. This report indicates that some patients may develop severe visual dysfunction without early treatment for the primary tumor.Keywords
This publication has 14 references indexed in Scilit:
- Paraneoplastic optic neuropathy associated with cerebellar choroid meningiomaEye, 2013
- Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathyJournal of Ophthalmic Inflammation and Infection, 2011
- Neuro-Ophthalmologic Manifestations of Paraneoplastic SyndromesJournal of Neuro-Ophthalmology, 2008
- CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinomaEye, 2007
- Small Cell Lung Carcinoma Presenting as Collapsin Response-Mediating Protein (CRMP) -5 Paraneoplastic Optic NeuropathyJournal of Neuro-Ophthalmology, 2006
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgGAnnals of Neurology, 2003
- Paraneoplastic Retinopathies and Optic NeuropathiesSurvey of Ophthalmology, 2003
- A case with paraneoplastic optic neuropathy presenting bitemporal hemianopsiaNeuro-Ophthalmology, 1991